Cited by 43Alzheimer's disease research and treatmentsDown syndrome and intellectual disability researchNeuroscience and Neuropharmacology Research

Synaptic actin stabilization protein loss in Down syndrome and Alzheimer disease

Open access
Lauterborn, Julie C., Cox, Conor D., Chan, See Wing, Vanderklish, Peter W., Lynch, Gary, Gall, Christine M.·2020·Brain Pathology

Abstract

Reduced spine densities and age‐dependent accumulation of amyloid β and tau pathology are shared features of Down syndrome (DS) and Alzheimer's disease (AD). Both spine morphology and the synaptic plasticity that supports learning depend upon the actin cytoskeleton, suggesting that disturbances in actin regulatory signaling might underlie spine defects in both disorders. The present study evaluated the synaptic levels of two proteins that promote filamentous actin stabilization, the Rho GTPase effector p21‐activated kinase 3 (PAK3) and Arp2, in DS vs. AD. Fluorescent deconvolution tomography was used to determine postsynaptic PAK3 and Arp2 levels for large numbers of excitatory synapses in the parietal cortex of individuals with DS plus AD pathology (DS + AD) or AD alone relative to age‐matched controls. Though numbers of excitatory synapses were not different between groups, synaptic PAK3 levels were greatly reduced in DS + AD and AD individuals vs. controls. Synaptic Arp2 levels also were reduced in both disorders, but to a greater degree in AD. Western blotting detected reduced Arp2 levels in the AD group, but there was no correlation with phosphorylated tau levels suggesting that the Arp2 loss does not contribute to mechanisms that drive tau pathology progression. Overall, the results demonstrate marked synaptic disturbances in two actin regulatory proteins in adult DS and AD brains, with greater effects in individuals with AD alone. As both PAK and the Arp2/3 complex play roles in the actin stabilization that supports synaptic plasticity, reductions in these proteins at synapses may be early events in spine dysfunction that contribute to cognitive impairment in these disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bpa.12779

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [6]Boros BD, Greathouse KM, Gentry EG, Curtis KA, Birchall EL, Gearing M, Herskowitz JH (2017) Dendritic spines provide cognitive resilience against Alzheimer’s disease. Ann Neurol. 82: 602– 14. 28921611 PMC5744899
  2. [28]Lauterborn JC, Kramár EA, Rice JD, Babayan AH, Cox CD, Karsten CA, Gall CM, Lynch G (2017) Cofillin activation is tmeporally assocaited with the cessation of growth in the developing hippocampus. Cereb Cortex. 27: 2640– 51. 27073215 PMC5964364

Cited by

Sorted by citations

Authors
Lauterborn, J. C., Cox, C. D., Chan, S. W., Vanderklish, P. W., Lynch, G., & Gall, C. M.
Affiliations
  • University of California, Irvine (US)
  • Scripps Research Institute (US)
Venue
Brain Pathology
Publisher
Wiley
Published
2019-09-08
Volume
30
Issue
2
Pages
319-331
ISSN
  • 1015-6305 (ISSN-L)
  • 1750-3639
OpenAlex
W2968516410
Cited by
43
References
64
Citations by year
2026: 1 · 2025: 2 · 2024: 8 · 2023: 18 · 2022: 2 · 2021: 7 · 2020: 4 · 2017: 1
FWCI
2.23
Type
journal article
Language
en
Open access
Locations
  • Brain Pathology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • National Institute on Aging (AG00096‐34, AG016573)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD079823, HD089491)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
Down syndrome, Alzheimer's disease, Arp2, Arp2/3 complex, dendritic spine density, actin cytoskeleton, synaptic plasticity, amyloid-beta, tau pathology, parietal cortex, cognitive impairment
MeSH terms
Actins, Alzheimer Disease, Down Syndrome, Female, Humans, Male, Middle Aged, Synapses, Actin-Related Protein 2, p21-Activated Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review